Citation Impact
Citing Papers
Antigen-Specific CD4+ T Cells Regulate Function of Myeloid-Derived Suppressor Cells in Cancer via Retrograde MHC Class II Signaling
2012
COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells
2011
Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer
2009
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity
2010
Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
2010
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
2008
Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
2009
IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
2009
Fas Signal Promotes Lung Cancer Growth by Recruiting Myeloid-Derived Suppressor Cells via Cancer Cell-Derived PGE2
2009
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
2009 Standout
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Head and neck squamous cell carcinoma
2020 Standout
Myeloid-derived suppressor cells coming of age
2018 Standout
A view on drug resistance in cancer
2019 StandoutNature
Thyroid cancer
2016 Standout
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
2013
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
2010
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Epigenetics: A Landscape Takes Shape
2007 Standout
Pancreatic cancer
2020 Standout
Epigenetic therapy of cancer: past, present and future
2006
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion
2006
Hallmarks of aging: An expanding universe
2023 Standout
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
2016 Standout
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Head and neck cancer
2008 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Coordinated regulation of myeloid cells by tumours
2012 Standout
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
2006
Nasopharyngeal carcinoma
2019 Standout
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
2008
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
2017
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
2008
Nonresolving Inflammation
2010 Standout
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
2012
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Thyroid Gland Malignancies
2015
Epigenetics in Cancer
2008 Standout
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
2010
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
2013
The use of combinations of monoclonal antibodies in clinical oncology
2015
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
2018
Inflammatory cell infiltration of tumors: Jekyll or Hyde
2007
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells
2009
Macrophages and cancer
2008
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Immunity, Inflammation, and Cancer
2010 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Amino acids and immune function
2007 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
2011
Targeting DNA repair mechanisms in cancer
2012
Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity
2010
Prospects for MEK inhibitors for treating cancer
2014
New treatment strategies for HPV-positive head and neck cancer
2013
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
2011
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
2009 Standout
Protective and pathogenic functions of macrophage subsets
2011 Standout
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Myeloid derived suppressor cells in human diseases
2011
Major and minor salivary gland tumors
2009
Cancer-related inflammation
2008 StandoutNature
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
2012
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Clinical, Safety, and Economic Evidence in Radioactive Iodine–Refractory Differentiated Thyroid Cancer: A Systematic Literature Review
2013
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer
2014
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Myeloid-Derived Suppressor Cells
2017
Histone Deacetylase Inhibitors as Anticancer Drugs
2017
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives
2008
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
2008
Head and Neck Cancer
2020 Standout
Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine
2006 StandoutNobel
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
2015
Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression
2007
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
2010
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
2008
Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
2013
Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells
2010
Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironmentviamyeloid-derived suppressor cells
2014
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Granulocytic Myeloid–Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level
2017
Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma
2007
Transcriptional regulation of myeloid-derived suppressor cells
2015
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2019
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
2007
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host
2007
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
2009
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell–expressed FasL
2011
Myeloid-Derived Suppressor Cells Contribute to Staphylococcus aureus Orthopedic Biofilm Infection
2014
The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment
2014
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Epigenetic regulation of redox state mediates persistent cardiorespiratory abnormalities after long‐term intermittent hypoxia
2016 StandoutNobel
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
2007
Subpopulations of myeloid‐derived suppressor cells impair T cell responses through independent nitric oxide‐related pathways
2013
Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis.
2009
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
2006
IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms
2021
Works of Jill Gilbert being referenced
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
2017
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group
2017
Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors
2012
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
2012
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
2015
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
2015
Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group
2006
The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms
2005
Evolution of clinical trials in head and neck cancer
2008
Pharmacokinetics of 5-Azacitidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies
2005
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
2005
ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).
2012
Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study.
2016
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
2014